[New CCR5 inhibitor antiretroviral drugs and integrase inhibitors]. / Nuevos fármacos antirretrovirales: inhibidores del CCR5 y de la integrasa.

Two new antiretroviral drugs belonging to a new drug family have recently been marketed in Spain. These are maraviroc (CCR5 correceptor inhibitor) and raltegravir (integrase inhibitor). These have the advantage of not presenting crossed resistance with other previously administered antiretroviral drugs, converting them into the cornerstone of the rescue treatment in the patient infected by a multiresistant viral strain. The scientific evidence available on these two drugs is reviewed in this work and its indications in the HIV infected patient are discussed.

Nuevos fármacos antirretrovirales: inhibidores del CCR5 y de la integras / New CCR5 inhibitor antiretroviral drugs and integrase inhibitors

Recientemente se han comercializado en Españados fármacos antirretrovirales que pertenecen anuevas familias farmacológicas: maraviroc (inhibidordel correceptor CCR5) y raltegravir (inhibidor de laintegrasa). Tienen la ventaja de no presentarresistencia cruzada con otros fármacosantirretrovirales administrados previamente, lo quelos convierte en la piedra angular del tratamiento derescate en el paciente infectado por una cepa viralmultirresistente. En este trabajo se revisa laevidencia científica disponible de estos dosfármacos, y se comentan cuáles son sus indicacionesen el paciente infectado por el virus de lainmunodeficiencia humana (VIH)

Two new antiretroviral drugs belonging to a newdrug family have recently been marketed in Spain.These are maraviroc (CCR5 correceptor inhibitor)and raltegravir (integrase inhibitor). These have theadvantage of not presenting crossed resistance withother previously administered antiretroviral drugs,converting them into the cornerstone of the rescuetreatment in the patient infected by a multiresistantviral strain. The scientific evidence available onthese two drugs is reviewed in this work and its indications in the HIV infected patient are discussed (AU)

Nuevos fármacos antirretrovirales: inhibidores del CCR5 y de la integrasa / New CCR5 inhibitor antiretroviral drugs and integrase inhibitors

Recientemente se han comercializado en Españados fármacos antirretrovirales que pertenecen anuevas familias farmacológicas: maraviroc (inhibidordel correceptor CCR5) y raltegravir (inhibidor de laintegrasa). Tienen la ventaja de no presentarresistencia cruzada con otros fármacosantirretrovirales administrados previamente, lo quelos convierte en la piedra angular del tratamiento derescate en el paciente infectado por una cepa viralmultirresistente. En este trabajo se revisa laevidencia científica disponible de estos dosfármacos, y se comentan cuáles son sus indicacionesen el paciente infectado por el virus de lainmunodeficiencia humana (VIH)

Two new antiretroviral drugs belonging to a newdrug family have recently been marketed in Spain.These are maraviroc (CCR5 correceptor inhibitor)and raltegravir (integrase inhibitor). These have theadvantage of not presenting crossed resistance withother previously administered antiretroviral drugs,converting them into the cornerstone of the rescuetreatment in the patient infected by a multiresistantviral strain. The scientific evidence available onthese two drugs is reviewed in this work and its indications in the HIV infected patient are discussed (AU)

[Multiple pulmonary nodules as an unusual manifestation of pulmonary tuberculosis. Description of 3 cases]. / Nódulos pulmonares múltiples como manifestación inusual de la tuberculosis pulmonar. Descripción de tres casos.

Pulmonary tuberculosis is still one of the more frequent diseases in our setting, adopting a wide variety of clinic as well as radiologic presentations. We present three cases of pulmonary tuberculosis with multiple bilateral pulmonary nodules of segmentary localization, one of them requiring thoracotomy to perform the diagnosis.

[Lupus vulgaris as initial manifestation of asymptomatic pulmonary tuberculosis]. / Lupus vulgar como manifestación inicial de tuberculosis pulmonar inadvertida.

A clinical case of a male with lupus lesion localized in scalp associated to a bilateral cavitated pulmonary tuberculosis which was non symptomatic. The cutaneous symptoms of tuberculosis is reviewed because the rareness of this presentation.